Key result
Clozapine use is linked to ~240% higher short-term perimyocarditis and increased long-term heart failure risk.
Why the study?
The risk of cardiac adverse events following clozapine use is debated and is unknown for the chemically related and widely used antipsychotics olanzapine and quetiapine.
Does exposure to clozapine, olanzapine, or quetiapine increase the risk of perimyocarditis or heart failure compared to no antipsychotic treatment?
Cohort (n=201,045)
Does exposure to clozapine, olanzapine, or quetiapine increase the risk of perimyocarditis or heart failure compared to no antipsychotic treatment?
Effect estimate: HR 3.4 (95% CI 1.6-7.3)
Absolute Event Rate: 0.16% vs 0.02%
Clozapine, but not olanzapine or quetiapine, is associated with a significantly increased risk of perimyocarditis within 2 months and heart failure within 3 years.
Authors
No takes yet. Share an insight, caveat, or question.
May support cardiac monitoring with clozapine; leaves open causality and generalizability pending randomized trials.
Clapham et al. (2023) conducted a cohort in Patients with antipsychotic dispensations (n=201,045). Clozapine vs. No antipsychotic treatment was evaluated on Perimyocarditis within two months (HR 3.4, 95% CI 1.6-7.3). Clozapine use tripled the short-term risk of perimyocarditis (HR 3.4) and increased the long-term risk of heart failure (HR 1.3) compared to no antipsychotic treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: